knowledge -WSS

knowledge

author：focus 2025-09-30 00:48:30 - browse：81466

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： A new House health package & hospitals’ new site

knowledge

WSS

A new deal aims to ramp up use of AI in rehab care decisions

Covid hospitalizations on the rise, Humana says

What American doctors can learn from their Israeli counterparts

NIH nominee Bertagnolli will get October confirmation hearing

Amazon on where the company's health care bets are headed next

New chief aims to remake Sanofi Genzyme

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

entertainment

The high cost of giving birth even with insurance

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

The cancer drug shortage isn’t new — and neither are the solutions

Why the advice to take all your antibiotics may be wrong

In age of alternative facts, a scholarly course on calling out crap

A rare thyroid diagnosis led to unexpected, all

DIEP, the 'gold standard' of breast reconstruction, is under threat

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

Alkermes shareholders re

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

Wikipedia

Trump Organization, Michael Cohen agree to settle million

Reframing the conversation around gain

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

House transparency, PBM reform bill gains bipartisan support

The (many) problems with a new study criticizing cancer screening

The 10 drugs up first for Medicare price negotiation

knowledge

focus

hotspot

focus